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Abstract
Background: We report the case of a giant intrathyroidal parathyroid adenoma weighing 59 g in a young woman
presenting acutely with severe hypercalcemia requiring correction and adequate preoperative management prior
to surgery. Parathyroid adenomas account for 85 % of cases of primary hyperparathyroidism. Those weighing more
than 3.5g are classified as giant parathyroid adenomas. There are only 25 cases of parathyroid adenomas weighing
over 30g reported in the literature.
With the wide availability of biochemical screening tests in Western countries, mildly elevated calcium levels are
often discovered incidentally. Our case is unusual for the extreme level of hypercalcemia, the patient’s young age,
and the weight of the adenoma, particularly in a developed country.
Case presentation: A 21-year-old Irish woman presented with a 3-week history of an enlarging right-sided neck
mass. There was no dysphagia, stridor, or symptoms of hyperthyroidism or hypercalcemia. On examination, there
was a firm painless swelling in the right lobe of her thyroid. Her thyroid function tests were normal. Corrected
serum calcium was markedly elevated at 3.96 mmol/L with hypophosphatemia of 0.35 mmol/L. She was treated
with bisphosphonates and fluids administered intravenously. Her parathyroid hormone level was over 20 times the
upper limit of normal. Ultrasound revealed a solid and cystic nodule in the lower pole of the right lobe of her
thyroid. Parathyroid scintigraphy demonstrated a 5×4 cm lesion which concentrated tracer.
A right-sided parathyroidectomy, right thyroid lobectomy, and level VI neck dissection were performed. An
encapsulated multiloculated solid cystic mass weighing 59 g was removed. There was no definite infiltration of the
capsule and MIB1 count was low at 1 % thus the specimen lacked the diagnostic features of carcinoma. On the
third postoperative day, hungry bone syndrome developed and calcium replacement administered intravenously
was required. At 1-year postoperative, she was weaned off calcium and alfacalcidol. A follow-up ultrasound showed
unremarkable residual thyroid.
Conclusions: Any patient with an isolated hypercalcemia warrants a thorough work-up. Hungry bone syndrome is
a potentially avoidable condition; thus the clinician should be highly attuned to the risk of hungry bone syndrome
post-parathyroidectomy, which correlates with the weight of the adenoma resected.
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Background
Primary hyperparathyroidism (PHPT) affects 22 per
100,000 people per year with a mean age of onset of 56
years and a female preponderance of 3:1 [1]. The incidence
in patients aged 12 to 28 years is less than 5 % [2]. Solitary
parathyroid adenomas account for 80 to 85 % of cases of
PHPT. Less common causes include multiple adenomas,
parathyroid hyperplasia, and parathyroid carcinoma.
The normal parathyroid gland weighs 50 to 70 mg. The
median weight of parathyroid adenomas is 600 mg [3, 4].
Adenomas weighing more than 3.5 g [3] are classified as
giant parathyroid adenomas (GPAs). In one series of 300
patients with PHPT, 5 % of resected adenomas weighed
more than 3.5 g [3]. The most frequent etiological associ-
ation with GPA is irradiation, as seen in Japanese survivors
of an atomic bomb [5]. In 2009, there had only been 16
cases of adenomas weighing over 30 g reported in the
literature [6]. A literature search of the past 5 years
revealed another nine cases of adenomas weighing over 30 g.
Our patient’s adenoma weighed nearly 59 g.
The largest adenoma described in the literature to date
weighed 145 g [7] in a 63-year-old woman with a
3-month history of headache and fatigue; corrected
serum calcium was 3.3 mmol/L. Another unusual case
was an 85-year-old woman from rural Ireland who pre-
sented with stridor and was found to have a 110 g para-
thyroid adenoma [8].
Case presentation
A 21-year-old Irish woman presented to an outside insti-
tution with a 3-week history of an enlarging right-sided
neck mass. She had no significant medical history
and was taking no medications. There was no dys-
phagia or stridor and she denied symptoms of hyper-
calcemia, hyperthyroidism, fevers, or weight loss. She
did report mild constipation and two episodes of
presyncope over the preceding weeks which were
precipitated by exercise.
Her family history was notable for her maternal grand-
mother who died of sudden cardiac death and two ma-
ternal aunts with hyperthyroidism and goitres. Her
mother had a duplex kidney system and was diagnosed
with hypertension at the age of 23, necessitating four
anti-hypertensive agents.
On examination, there was a firm painless swelling in
the right lobe of her thyroid with no palpable lymph-
adenopathy. She was tachycardic with a heart rate (HR)
of 112 but not hypotensive with blood pressure (BP)
116/80. Thyroid and renal function tests were normal:
her serum creatinine was 64 mmol/L (44 to 86) and her
estimated glomerular filtration rate (eGFR) was 124 mL/
minute/1.73 m2 (normal ≥90 mL/minute/1.73 m2). How-
ever, her corrected serum calcium was markedly elevated
at 3.96 mmol/L (2.2 to 2.6) with a hypophosphatemia of
0.35 mmol/L (0.80 to 1.5). Her albumin was 49 g/L (35
to 50). She was admitted acutely for fluids and bispho-
sphonates administered intravenously. Her calcium
responded quickly, falling to 2.46 mmol/L within 3 days
(Figs. 1 and 2). An ultrasound of her thyroid revealed a
solid and cystic nodule in the lower pole of the right
lobe of her thyroid measuring 5×4 cm. This was initially
presumed to be a thyroid nodule and she was discharged
with a scheduled out-patient appointment for thyroid
fine-needle aspiration. However, 2 days later her para-
thyroid hormone (PTH) level was found to be over 20
times the upper limit of normal: 138.4 pmol/l (1.6 to
6.9). The PTH assay used was a second-generation
Roche Platform electrochemiluminescence immunoassay
“ECLIA” which measures intact PTH.
Six days later she was admitted to our institution. Her
corrected calcium had risen again and now measured
2.73 mmol/L. Her vitamin D level was low at 35 nmol/L
(<50) and her alkaline phosphatase was 143 IU/L (30 to
130). Her alkaline phosphatase levels rose over 5 days to
240 IU/L (30 to 130). A chest radiograph showed no
osseous abnormalities.
The differential diagnosis included parathyroid aden-
oma, parathyroid hyperplasia, and parathyroid carcin-
oma. Multiple endocrine neoplasia type 1 (MEN1) was
also a possibility, particularly given her young age.
Parathyroid scintigraphy (Tc99m sestamibi scan)
demonstrated a lesion posterior to the right lobe of her
thyroid which concentrated tracer and measured 7 to 10
cm in maximum length (Fig. 3). Her urinary calcium ex-
cretion was elevated at 9 mmol/24 hours (2.5 to 7.5/24
hours). Her prolactin level was normal, as were her
urinary catecholamines and metanephrines.
Following surgical planning and adequate preoperative
work-up, a right-sided parathyroidectomy, right thyroid
lobectomy, and level VI neck dissection were performed.
A level VI neck dissection was performed as there was a
strong clinical suspicion of parathyroid carcinoma in
view of the size of the enlarging lesion and her PTH
levels. Her PTH was measured 4 days prior to surgery:
185 pmol/l (1.6 to 6.9). On postoperative day one, her
PTH level had fallen to 7.6 pmol/l (1.6 to 6.9). An
encapsulated multiloculated solid cystic mass measuring
80×55×30 mm and weighing 58.8 g was removed (Fig. 4a,
b). There were focal areas of hemorrhage within the spe-
cimen. This was an atypical parathyroid adenoma due to
its size and due to the presence of some cells and groups
of cells in the capsule. There was no infiltration of the
capsule meaning that the tumor cells did not extend
beyond the capsule into the surrounding tissue. There
was no perineural or vascular invasion and MIB1 count
was low at 1 %; thus, the specimen lacked the diagnostic
features of carcinoma (Fig. 4c). All ten dissected lymph
nodes were free from tumor.
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Her corrected serum calcium fell precipitously to a
nadir of 1.76 mmol/L on the third postoperative day
(Fig. 1). She developed tingling in her hands and feet
and calcium replacement administered intravenously
was required. Her alkaline phosphatase levels rose from
240 IU/L (30 to 130) preoperatively to 404 IU/L (30 to
130) on the sixth postoperative day. Her phosphate fell
to a nadir of 0.43 mmol/L (0.80 to 1.5) and her magne-
sium fell to 0.59 mmol/L (0.7 to 1.0). These were both
replaced orally. She was discharged well on the sixth
Fig. 1 Demonstration of the decline in serum calcium with fluids and bisphosphonates administered intravenously. This figure also depicts the
immediate fall in serum calcium, phosphate and magnesium following parathyroidectomy. IV intravenous
Fig. 2 This graph demonstrates the immediate fall in serum calcium following parathyroidectomy
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postoperative day on calcium administered orally and
alfacalcidol (1α-hydroxyvitamin D3). At 1-year postoper-
ative, she is asymptomatic and has been weaned off both
agents. Her serum calcium and PTH are within normal
range and a follow-up ultrasound showed unremarkable
residual thyroid.
Discussion
Before transfer to our center, this patient was suspected
to have a thyroid nodule and was scheduled for thyroid
fine-needle aspiration. Fortunately a PTH level was
checked and the correct diagnosis was reached. This
case highlights that an intrathyroidal parathyroid aden-
oma could easily be mistaken for a thyroid nodule.
In the past, patients were more likely to present with
extreme hypercalcemia and profound skeletal disease.
With the availability of biochemical screening tests in
Western countries, patients are now more likely to
present with minor symptoms and mildly elevated serum
calcium levels which are often discovered incidentally.
Our case is unusual for the level of hypercalcemia, the
acute presentation, the patient’s young age, and the
weight of the adenoma, particularly in a developed coun-
try such as Ireland. The cystic mass we have described is
very uncommon. Cystic parathyroid lesions make up less
than 0.01 % of all neck masses [9]. They may be pure
retention cysts or created by degeneration of an aden-
oma or carcinoma. In our case there was possibly partial
cystic degeneration of the gland because of its huge size
and probable long-standing nature, although the histo-
pathological sections showing cysts did not reveal cystic
degeneration [10]. A palpable neck mass is extremely
rare in PHPT [11].
Several case series have supported the hypothesis that
GPAs represent a distinct clinical entity with specific gen-
omic aberrations [3, 12]. When compared to patients with
parathyroid adenomas, the GPA group contains a higher
relative number of male cases and cases of single gland
disease (versus multiglandular disease) [12]. The weight of
the gland correlates with functionality and thus serum
calcium levels [13]. There are only isolated case reports of
non-functioning GPAs [14, 15]. Patients with GPA have
higher mean preoperative PTH and serum calcium levels
but are less likely to have symptoms of hypercalcemia [3].
The mechanism whereby they are asymptomatic remains
unclear. This subset of asymptomatic patients will natur-
ally present later thus these adenomas may grow to enor-
mous dimensions before detection. The history of rapid
onset in this case is unusual. We postulate that this was
due to hemorrhage in the cystic component of the lesion.
Such rapid enlargement would not otherwise be expected
with a low MIB1 count. Ultrasonography may underesti-
mate the size of these adenomas as only a proportion of
the adenoma may be visualized transcervically [16].
Hungry bone syndrome (HBS) is the name given to
the rapid severe decline in serum calcium due to the
Fig. 3 Single-photon emission computed tomography/computed tomography image at 2.5 hours post-radiotracer injection (Tc99m sestamibi)
demonstrating a large lesion in the right lobe of the thyroid
Fig. 4 Giant parathyroid adenoma. a Gross specimen following resection. b Cross-sections of the multiloculated cystic mass. c Adenomatous cells
under microscopy with adjacent normal thyroid tissue
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abrupt withdrawal of PTH following parathyroidectomy
in patients with severe PHPT. Our patient developed
HBS on the third postoperative day. The incidence of
HBS in patients post-parathyroidectomy for PHPT was
13 % in one case series [17]. The volume of the gland
resected correlates with the risk of HBS and is more
predictive of HBS than other risk factors such as older
age, preoperative blood urea nitrogen or alkaline phos-
phatase concentrations [17]. Treatment involves oral
and/or intravenous administration of calcium and cor-
rection of magnesium. In our case the acute drop in
phosphate level postoperatively resulted in cautious
phosphate supplementation being administered orally
from day 3 to 6 postoperatively. However, when
reviewed by the endocrinology team this supplementa-
tion was discontinued on day 6, in keeping with the best
practice guidelines of avoiding phosphate replacement in
the setting of HBS as this may exacerbate hypocalcemia.
Prophylactic measures such as preoperative vitamin D
supplementation and preoperative bisphosphonates are
currently being studied [18].
GPAs have both overlapping and distinguishing
features when compared with parathyroid adenomas and
carcinomas. GPAs are genetically similar to “usual”
parathyroid adenomas with regards to frequent MEN1
mutations and infrequent hyperparathyroidism 2 gene
(HRPT2) mutations. However, they are more akin to car-
cinoma in terms of loss of adenomatous polyposis coli
(APC) immunoreactivity, parafibromin expression, and
gain of chromosome 5 [12]. APC has the potential to be-
come a valuable molecular screening tool that could
help risk stratification of atypical parathyroid adenomas
[19]. HRPT2 gene and parafibromin staining are useful
methods of detecting carcinoma when other tests reveal
negative results and clinically carcinoma is a possibility.
Unfortunately they are not available in our institution.
GPAs may mimic parathyroid carcinomas due to their
large glandular size and extreme level of hypercalcemia.
Endocrinologists have also questioned whether GPAs
possess malignant potential [20]. Although follow-up
time is relatively short, no recurrences have been
reported [12]. Nor is there any increased incidence of
persistent or recurrent hyperparathyroidism when
compared to “regular-sized” parathyroid adenomas [3].
However, because of the molecular resemblance to car-
cinomas, patients with atypical adenomas should be
followed up carefully.
Conclusions
Acute PHPT with severe hypercalcemia is a rare and ser-
ious disorder [21, 22]. Any patient with an isolated severe
hypercalcemia, particularly a patient as young as ours,
warrants emergency admission and a thorough endocrino-
logical work-up. Significantly elevated serum calcium is
more suggestive of hypercalcemia of malignancy or of
parathyroid carcinoma than of parathyroid adenoma. An
intrathyroidal mass may be a GPA. Postoperatively, HBS is
a serious and potentially avoidable condition. The clin-
ician should be highly attuned to the risk of hypocalcemia
following resection of GPA and maintain a low threshold
for calcium and/or vitamin D supplementation.
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